(3R,4R)-A2-32-01

CAS No. 1359752-95-6

(3R,4R)-A2-32-01( —— )

Catalog No. M32751 CAS No. 1359752-95-6

(3R,4R)-A2-32-01 is the (R,R)-enantiomer of A2-32-01 and has potential antibacterial activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 225 In Stock
5MG 424 In Stock
25MG 1316 In Stock
50MG 1711 In Stock
100MG 2250 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (3R,4R)-A2-32-01
  • Note
    Research use only, not for human use.
  • Brief Description
    (3R,4R)-A2-32-01 is the (R,R)-enantiomer of A2-32-01 and has potential antibacterial activity.
  • Description
    (3R,4R)-A2-32-01 (compound 24(R,R)), the (R,R)-enantiomer of A2-32-01, is a Staphylococcus aureus caseinolytic protease (SaClpP) inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1359752-95-6
  • Formula Weight
    301.42
  • Molecular Formula
    C19H27NO2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 200 mg/mL (663.53 mM; Ultrasonic )
  • SMILES
    C(CCCCCCC=C)[C@@H]1[C@@H](CCC=2C=CC=NC2)OC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Malte Gersch, et al. The mechanism of caseinolytic protease (ClpP) inhibition. Angew Chem Int Ed Engl. 2013 Mar 4;52(10):3009-14.?
molnova catalog
related products
  • GSK1733953A

    GSK1733953A can be used as a small molecule Mycobacterium tuberculosis respiration inhibitor with an inhibitory effect on MenG activity and an IC50 value of 2.6 ± 0.6 μM.

  • Negamycin

    A dipeptide antibiotic that inhibits the initiation of protein synthesis; also restores dystrophin expression in skeletal and cardiac muscles of the mdx mouse.

  • I-2906

    A novel isocitrate lyase (ICL) inhibitor that displays showed excellent anti-Mycobacterium tuberculosisl activities and low cytotoxicity.